



7 May 2013

ASX RELEASE

Novogen Oncology Discovery Library and Indications Expand

Novogen today announces completion of screening of its second generation of *super-benzopyrans* in its ongoing drug discovery platform.

The Company's current lead drug candidate, CS-6, is a product of the first generation of compounds.

The discovery program aims to use the Company's proprietary 'bend' technology to both strengthen the Company's intellectual property position as well as identifying new lead compounds. Using CS-6 as the starting point, the program constructs new compounds of differing shape and increasing complexity. The objective is to discover new lead candidates with potent activity against various types of cancer stem cells and regular cancer cells.

Laboratory screening now has identified melanoma and pancreatic cancer as being highly sensitive to second-generation compounds, with two compounds showing particularly high potency.

Newly appointed Novogen Chief Scientific Officer, Dr David Brown, said today, "the identification of two new hit compounds against pancreatic cancer and melanoma nicely complements our pipeline of CS-6 with its key indications of glioblastoma and ovarian cancer."

"Our task now is to decide which of these two new compounds we will fast-track through to the clinic in parallel with CS-6," he added.

President of Novogen North America Inc, Dr Andrew Heaton, said today, "today's results confirm our belief in the exciting potential of our ability to 'bend' small molecules to deliver specific activity against specific forms of cancer, and to meet our mission of developing a family of drugs providing comprehensive activity against both regular cancer cells and their progenitor cells."

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

About Cancer Stem Cells

Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a subpopulation of cells within many types of cancer that are responsible for driving the growth and spread of the cancer. CSC typically are resistant to radiotherapy and chemotherapy and are thought to be responsible for cancer recurrence following therapy. Targeting CSC is a new direction in oncology drug development as a means of preventing cancer recurrence.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

M: (61) 0459 200 095

E: Graham.Kelly@novogen.com

Please note that the Company currently is relocating offices and that the original phone numbers no longer are in use. New contact details will be available shortly.

Further information is available on the Company's web site, www.novogen.com